Regulus Therapeutics Future Growth
Future criteria checks 0/6
Regulus Therapeutics is forecast to grow earnings and revenue by 47.4% and 56.1% per annum respectively while EPS is expected to grow by 54.9% per annum.
Key information
47.4%
Earnings growth rate
54.9%
EPS growth rate
Biotechs earnings growth | 24.4% |
Revenue growth rate | 56.1% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 06 May 2024 |
Recent future growth updates
Recent updates
Regulus surges 15% after Phase 1 data for kidney disease candidate
Sep 12Regulus Therapeutics GAAP loss per share narrows
Aug 11Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?
Oct 12The Read On Regulus Therapeutics
Aug 03We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now
Jun 09Regulus reports top-line data from early-stage RGLS4326 trial in polycystic kidney disease
May 03Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)
Mar 13Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year
Mar 10Regulus Therapeutics announces closing of $19.4M private placement
Dec 08Regulus Therapeutics EPS beats by $0.17, beats on revenue
Nov 05Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -54 | N/A | N/A | 2 |
12/31/2025 | N/A | -47 | N/A | N/A | 3 |
12/31/2024 | N/A | -34 | N/A | N/A | 4 |
12/31/2023 | N/A | -30 | -27 | -27 | N/A |
9/30/2023 | N/A | -29 | -28 | -27 | N/A |
6/30/2023 | N/A | -28 | -27 | -27 | N/A |
3/31/2023 | N/A | -29 | -28 | -27 | N/A |
12/31/2022 | N/A | -28 | -26 | -26 | N/A |
9/30/2022 | N/A | -29 | -27 | -27 | N/A |
6/30/2022 | N/A | -30 | -26 | -26 | N/A |
3/31/2022 | N/A | -29 | -25 | -25 | N/A |
12/31/2021 | N/A | -28 | -24 | -24 | N/A |
9/30/2021 | 5 | -22 | -13 | -13 | N/A |
6/30/2021 | 10 | -15 | -12 | -12 | N/A |
3/31/2021 | 10 | -16 | -12 | -12 | N/A |
12/31/2020 | 10 | -16 | -13 | -13 | N/A |
9/30/2020 | 5 | -19 | -21 | -21 | N/A |
6/30/2020 | 0 | -23 | -21 | -21 | N/A |
3/31/2020 | 0 | -21 | -22 | -21 | N/A |
12/31/2019 | 7 | -19 | -20 | -20 | N/A |
9/30/2019 | 7 | -22 | -19 | -19 | N/A |
6/30/2019 | 7 | -27 | -26 | -26 | N/A |
3/31/2019 | 7 | -36 | -32 | -32 | N/A |
12/31/2018 | 0 | -49 | -43 | -43 | N/A |
9/30/2018 | 0 | -55 | -50 | -50 | N/A |
6/30/2018 | 0 | -60 | -51 | -51 | N/A |
3/31/2018 | 0 | -68 | -56 | -56 | N/A |
12/31/2017 | 0 | -72 | -59 | -59 | N/A |
9/30/2017 | 0 | -77 | N/A | -63 | N/A |
6/30/2017 | 0 | -81 | N/A | -67 | N/A |
3/31/2017 | 1 | -81 | N/A | -67 | N/A |
12/31/2016 | 1 | -82 | N/A | -57 | N/A |
9/30/2016 | 12 | -69 | N/A | -59 | N/A |
6/30/2016 | 14 | -63 | N/A | -55 | N/A |
3/31/2016 | 17 | -62 | N/A | -48 | N/A |
12/31/2015 | 21 | -56 | N/A | -50 | N/A |
9/30/2015 | 14 | -71 | N/A | -44 | N/A |
6/30/2015 | 13 | -67 | N/A | -41 | N/A |
3/31/2015 | 10 | -58 | N/A | -42 | N/A |
12/31/2014 | 8 | -57 | N/A | -40 | N/A |
9/30/2014 | 9 | -36 | N/A | -37 | N/A |
6/30/2014 | 14 | -29 | N/A | -33 | N/A |
3/31/2014 | 18 | -24 | N/A | -30 | N/A |
12/31/2013 | 20 | -19 | N/A | -28 | N/A |
9/30/2013 | 17 | -24 | N/A | -18 | N/A |
6/30/2013 | 14 | -27 | N/A | -14 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RGLS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RGLS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RGLS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RGLS is forecast to have no revenue next year.
High Growth Revenue: RGLS is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RGLS's Return on Equity is forecast to be high in 3 years time